Novel Therapeutic Targets on the Horizon: An Analysis of Clinical Trials on Therapies for Bone Metastasis in Prostate Cancer
W Zhou, W Zhang, S Yan, K Zhang, H Wu, H Chen… - Cancers, 2024 - mdpi.com
Simple Summary Prostate cancer is the most common non-cutaneous malignancy among
men in the United States. Bone metastases and health are crucial issues in prostate cancer …
men in the United States. Bone metastases and health are crucial issues in prostate cancer …
Long-term outcomes of salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy: not as good as previously thought
Background Long-term outcomes of patients treated with salvage lymph node dissection
(sLND) for nodal recurrence of prostate cancer (PCa) remain unknown. Objective To …
(sLND) for nodal recurrence of prostate cancer (PCa) remain unknown. Objective To …
Oligometastatic prostate cancer: current status and future challenges
H Jadvar, AL Abreu, LK Ballas… - Journal of Nuclear …, 2022 - Soc Nuclear Med
In accordance with the spectrum theory of metastatic disease, an oligometastatic clinical
state has been proposed as an intermediary step along the natural history of cancer with few …
state has been proposed as an intermediary step along the natural history of cancer with few …
[HTML][HTML] Toxicity and efficacy of local ablative, image-guided radiotherapy in gallium-68 prostate-specific membrane antigen targeted positron emission tomography …
T Hölscher, M Baumann, J Kotzerke, K Zöphel… - European urology …, 2022 - Elsevier
Background Local ablative radiotherapy (aRT) of oligometastatic prostate cancer (PCa) is
very promising and has become a focus of current clinical research. Objective We …
very promising and has become a focus of current clinical research. Objective We …
Outcome of patients with biochemical recurrence of prostate cancer after PSMA PET/CT-directed radiotherapy or surgery without systemic therapy
Background Radiotherapy (RT) and surgery are potential treatment options in patients with
biochemical recurrence (BCR) following primary prostate cancer treatment. This study …
biochemical recurrence (BCR) following primary prostate cancer treatment. This study …
[HTML][HTML] Accuracy of 68Ga-PSMA-11 PET/CT and multiparametric MRI for the detection of local tumor and lymph node metastases in early biochemical recurrence of …
M Radzina, M Tirane, L Roznere… - American journal of …, 2020 - ncbi.nlm.nih.gov
Anatomical and functional imaging plays a decisive role for detection and staging, of
prostate cancer both primarily and post-treatment. While multiparametric MRI offers …
prostate cancer both primarily and post-treatment. While multiparametric MRI offers …
Five‐year outcomes of fractionated stereotactic body radiotherapy for oligometastatic prostate cancer from the TRANSFORM phase II trial
AW See, P Conway, M Frydenberg… - … Journal of Cancer, 2024 - Wiley Online Library
Metastasis‐directed therapy (MDT) for oligometastatic prostate cancer (PCa), including
stereotactic body radiotherapy (SBRT), has shown promise but is still considered …
stereotactic body radiotherapy (SBRT), has shown promise but is still considered …
Oncological outcomes of metastasis-directed therapy in oligorecurrent prostate cancer patients following radical prostatectomy
G Devos, C Berghen, H Van Eecke, AV Stichele… - Cancers, 2020 - mdpi.com
Several retrospective and a few prospective studies have shown that metastasis-directed
therapy (MDT) could delay clinical progression and postpone the initiation of systemic …
therapy (MDT) could delay clinical progression and postpone the initiation of systemic …
Detection Efficacy of 18F‐rhPSMA‐7.3 PET/CT and Impact on Management in Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy …
I Rauscher, A Karimzadeh, K Schiller… - Journal of Nuclear …, 2021 - Soc Nuclear Med
Radiohybrid prostate-specific membrane antigen (rhPSMA) ligands are a new class of 18F-
labeled PSMA-targeting agents. 18F-rhPSMA-7.3 is a lead compound that is currently under …
labeled PSMA-targeting agents. 18F-rhPSMA-7.3 is a lead compound that is currently under …
Management of bone metastasis in prostate cancer
K Nishimura - Journal of Bone and Mineral Metabolism, 2023 - Springer
Progression of bone metastases is the primary cause of death in prostate cancer, and
skeletal-related events (SREs), including pathologic fractures, spinal cord compression …
skeletal-related events (SREs), including pathologic fractures, spinal cord compression …